How Immunotherapy of Cancer May Create Novel Clinical Utilities for HLA Typing

Written by Dr. Attila Bérces (Founder and Chairman, Omixon) The article was originally published in ASHI Quarterly Q3 2017   While the role of HLA has been demonstrated in over hundred diseases, its clinical utility and impact outside transplantation has been limited. Transplantation still dominates the demand for HLA genotyping....

 

Read more